drugset / Trial / NCT05005741
The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
Phase 4
Unknown
120 enrolled
Second Xiangya Hospital of Central South University
First Affiliated Hospital of Harbin Medical University · collabGuangdong Provincial People's Hospital · collabThe First Affiliated Hospital of Henan University of Science and Technology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a multi-center, open label, randomized controlled trial that main purpose of this study is to evaluate the differences of glucose control and weight loss between Beinaglutide and Dulaglutide in type 2 diabetes with overweight or or Obesity.
Timeline
- Start
- 2021-05-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Beinaglutide | Protein / enzyme biologic | 0.2 mg | Subcutaneous |
| Comparator | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |